- DKK547.10m
- DKK499.72m
- DKK40.29m
Brief: BioPorto Maintains Guidance For 2023
Brief: BioPorto Q2 EBIT at DKK -20.9 Million
Brief: BioPorto: Completion Of Rights Issue
Brief: Bioporto A/S Announces Results Of Rights Issue
Brief: Bioporto Says Initiates A Rights Issue With Proceeds Of Up To About Dkk 59.4 Mln
Brief: BioPorto Q1 Net Income at DKK -16.1 Million
Brief: Bioporto Q4 Adj EBITDA Loss Down At 17.9 Mln
Brief: Bioporto Sees FY 2023 Revenue Between Approximately DKK 30 Mln To 33 Mln
Brief: Bioporto Submits Application For Marketing Authorization Of NGAL Test To The U.S. Food And Drug Administration
Brief: Bioporto Q2 Adjusted EBITDA Loss Of DKK 17.1 Mln
Brief: Bioporto Achieves Targeted Enrollment In Clinical Study Supporting FDA De Novo Submission For Ngal Test In U.S.
Brief: Bioporto Appoints Dr. Prasad Devarajan As Senior Medical Director
Brief: Bioporto Q1 Loss Flat At DKK 18.2 Mln
Brief: Bioporto Expects FY 2022 EBIT Loss Of DKK 95-100 Mln
Brief: Bioporto Completes Rights Issue
Brief: Bioporto Intends To Raise Up To DKK 100.4 Million In Share Issue
Brief: Bioporto Says U.S. FDA Does Not Recommend That Co Pursue An EUA For NGAL Assay
Brief: Bioporto Q3 EBIT Loss Narrows To DKK 14.5 Mln
Brief: BioPorto Appoints Neil Goldman As New CFO